Skip to main content
SpringerLink
Log in

Management and Treatment of Diabetes Mellitus

  • Chapter
  • First Online:
Diabetes

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 771))

Abstract

Management of patients with Type 2 diabetes mellitus (T2DM) demands a comprehensive approach which includes diabetes education, an emphasis on life style modification, achievement of good glycemic control, minimization of cardiovascular risk, and avoidance of drugs that can aggravate glucose or lipid metabolism, and screening for diabetes complications. Comprehensive diabetes management can delay the progression of complication and maximize the quality of life. Acquiring knowledge about diabetes is an essential part of diabetes management, and even more important is to make the patient aware of this chronic disease. “For a diabetic patient, knowledge and understanding are not a part of treatment—they are the treatment.”

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Steven RG. Emerging epidemic: diabetes in older adults: demography, economic impact, and pathophysiology. Diabetes Spectrum 2006; 19: 221–228.

    Article  Google Scholar 

  2. Norris SL, Zhang X, Avenell A et al. Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis. Am J Med 2004; 117: 762.

    Article  PubMed  Google Scholar 

  3. Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity-related health risk factors. JAMA 2003; 289(l): 76–79.

    Article  PubMed  Google Scholar 

  4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854–865.

    Google Scholar 

  5. Patel A et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24): 2560–2572.

    Article  CAS  PubMed  Google Scholar 

  6. White NH, Danis RP. Davis MD et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med 2011; 171(5): 412–420.

    Article  PubMed  Google Scholar 

  7. Funnell MM, Brown TL, Childs BP et al. National standards for diabetes self-management education. Diabetes Care 2007; 30: 1630.

    Article  PubMed  Google Scholar 

  8. Karter AJ, Parker MM, Moffet Hh et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 2006; 29(8): 1757–1763.

    Article  PubMed  Google Scholar 

  9. Goldstein DE, Little RR, Lorenz RA et al. Tests of glycemia in diabetes. Diabetes Care 2004; 27: 1761.

    Article  PubMed  Google Scholar 

  10. Miller CK, Edwards L, Kissling G et al. Nutrition education improves metabolic outcomes among older adults with diabetes mellitus. Prev Med 2002; 34(2): 252–259.

    Article  PubMed  Google Scholar 

  11. Bantle JP, Wylie-Rosett J, Albright AL et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008; 31Suppl 1: S61.

    CAS  PubMed  Google Scholar 

  12. Standards of medical care in diabetes. Diabetes Care 2010; 33Suppl 1: S11.

    Google Scholar 

  13. Masharani U. Diabetes mellitus & hypoglycemia. In: McPhee SJ, Papadakis MA. eds. Current Medical Diagnosis and Treatment 2010. McGraw-Hill: New York City, 2010: 1079–1122.

    Google Scholar 

  14. Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115(1): 114–126.

    Article  PubMed  Google Scholar 

  15. Klein S, Burke LE, Bray GA et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity and Metabolism. Circulation 2004; 110(18): 2952–2967.

    Article  PubMed  Google Scholar 

  16. Lawson ML, Kirk S, Mitchell T et al. One-year outcomes of Roux-en-Y gastric bypass for morbidly obese adolescents. J Pediatr Surg 2006; 41(1): 137–143.

    Article  PubMed  Google Scholar 

  17. O’Brien PE, Sawyer SM, Laurie C et al. Laparoscopic adjustable gastric banding in severely obese adolescents: a randomized trial. JAMA 2010; 303(6):519–526.

    Article  CAS  Google Scholar 

  18. Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery. Am J Med 2009; 122: 248–256.

    Article  PubMed  Google Scholar 

  19. Colquhoun AJ, Nicholson KG, Botha JL et al. Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. Epidemiol Infect 1997; 119: 335–341.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Bridges CB, Fukuda K, Uyeki TM et al. Prevention and control of influenza. Recommendations of the Advisory-Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2002; 51: 1–31.

    PubMed  Google Scholar 

  21. Fisher L, Skaff MM, Mullan JT et al. Clinical depression versus distress among patients with type 2 diabetes: not just a question of semantics. Diabetes Care 2007; 30: 542–548.

    Article  PubMed  Google Scholar 

  22. Ismail K, Winkley K, Rabe-Hesketh S. Systematic review and meta-analysis of randomized controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. Lancet 2004; 363: 1589.

    Article  PubMed  Google Scholar 

  23. Turner RC, Cull CA, Frighi V et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352(9131): 837–853.

    Article  Google Scholar 

  24. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281(21): 2005–2012.

    Article  PubMed  Google Scholar 

  25. Nathan DM, Buse JB, Davidson MB et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Monami M, Lamanna C, Marchionni N et al. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: Diabetes Res Clin Pract 2008; 79: 196.

    Article  CAS  PubMed  Google Scholar 

  27. Bolen S, Feldman L, Vassy J et al. Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus. Ann Intern Med 2007; 147: 386.

    Article  PubMed  Google Scholar 

  28. Zeller M, Danchin N, Simon D et al. Impact of type of pre-admission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 2010; 95(11): 4993–5002.

    Article  CAS  PubMed  Google Scholar 

  29. Eurich DT, Simpson SH, Majumdar SR et al. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes. Pharmacotherapy 2005; 25: 810–816.

    Article  CAS  PubMed  Google Scholar 

  30. Groop LC, Pelkonen R, Koskimies S et al. Secondary failure to treatment with oral antidiabetic agents in non-insulin-depeudeut diabetes. Diabetes Care 1986; 9: 129–133.

    Article  CAS  PubMed  Google Scholar 

  31. Matthews DR, Cull CA. Stratton IM et al. UKPDS 26: sulphonylurea failure in non-insulin dependent diabetic patients over six years. Diabet Med 1998; 15: 297–303.

    CAS  PubMed  Google Scholar 

  32. Tessier D, Dawson K. Tetrault JP, Bravo G et al. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994; 11(10): 974–980.

    Article  CAS  PubMed  Google Scholar 

  33. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17(6): 467–473.

    Article  CAS  PubMed  Google Scholar 

  34. Arruda-Olson AM, Patch RK et al. Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction. Mayo Clin Proc 2009; 84(l): 28–33.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Langer O, Conway DL, Berkus MD et al. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343(16): 1134–1138.

    Article  CAS  PubMed  Google Scholar 

  36. Langer O, Yogev Y, Xenakis EM et al. Insulin and glyburide therapy: dosage, severity level of gestational diabetes, and pregnancy outcome. Am J Obstet Gynecol 2005; 192(1): 134–139.

    Article  CAS  PubMed  Google Scholar 

  37. Conway DL, Gonzales O, Skiver D. Use of glyburide for the treatment of gestational diabetes: the San Antonio experience. J Matern Fetal Neonatal Med 2004; 15: 51.

    Article  CAS  PubMed  Google Scholar 

  38. Rochon M. Rand L, Roth L et al. Glyburide for the management of gestational diabetes: risk factors predictive of failure and associated pregnancy outcomes. Am J Obstet Gynecol 2006; 195: 1090.

    CAS  PubMed  Google Scholar 

  39. Fuhlendorff J, Rorsman P, Kofod H et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47(3): 345–351.

    Article  CAS  PubMed  Google Scholar 

  40. Moses R, Slobodniuk R, Boyages S et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22(1): 11: 9–24.

    Google Scholar 

  41. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333(9): 541–549.

    Article  Google Scholar 

  42. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574.

    Article  CAS  PubMed  Google Scholar 

  43. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854–865.

    Google Scholar 

  44. UKPDS 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310(6972): 83–88.

    Article  Google Scholar 

  45. Stumvoll M. Nurjhan N, Perriello G et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333(9): 550–554.

    Article  CAS  PubMed  Google Scholar 

  46. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574.

    Article  CAS  PubMed  Google Scholar 

  47. Zhou G, Myers R, Li Y, Chen Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108(8): 1167–1174. http://reference.medscape.com/medline/abstract/20702526.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Kasia JL, Clifford JB, Silvio EI. Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency. Diabetes Care 2011; 34: 1431–1436.

    Article  CAS  Google Scholar 

  49. Schernthaner G, Matthews DR, Charbonnel B et al. J Clin Endocrinol Metab 2004; 89(12): 6068–6076.

    Article  CAS  PubMed  Google Scholar 

  50. Kipnes MS, Krosnick A, Rendell MS et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus. Am J Med 2001; 111: 10.

    Article  CAS  PubMed  Google Scholar 

  51. Schwartz S, Raskin P, Fonseca V et al. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med 1998; 338(13): 861–866.

    Article  CAS  PubMed  Google Scholar 

  52. Iwamoto Y, Kosaka K, Kuzuya T et al. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996; 19(2): 151–156.

    Article  CAS  PubMed  Google Scholar 

  53. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106.

    Article  PubMed  Google Scholar 

  54. Vidal-Puig AJ, Considine RV, Jimenez-Linan M et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, andregulation by insulin and glucocorticoids. J Clin Invest 1997; 99(10): 2416–2422.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Gervois P, Fruchart JC, Stack B. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab 2007; 3(2): 145–156.

    Article  CAS  PubMed  Google Scholar 

  56. Chiquette E, Ramirez G. Defronzo R. TI A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164(19): 2097–2104.

    Article  CAS  PubMed  Google Scholar 

  57. Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28(7): 1547–1554.

    Article  CAS  PubMed  Google Scholar 

  58. Winkelmayer WC, Setoguchi S, Levin R et al. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008; 168(21): 2368–2375.

    Article  PubMed  Google Scholar 

  59. Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med 2007; 356: 2457–2471. http://www.nejm.org/toc/nejm/356/24/.

    Article  CAS  PubMed  Google Scholar 

  60. Rosen CJ. The Rosiglitazone Story: Lessons from an FDA Advisory Committee Meeting. N Engl J Med 2007; 357: 844–846. http://www.nejm.Org/toc/nejm/357/9/.

    Article  CAS  PubMed  Google Scholar 

  61. Singh S.LokeYK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298(10): 1189–1195.

    Article  CAS  PubMed  Google Scholar 

  62. Winkelmayer WC, Setoguchi S, Levin R et al. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008; 168(21): 2368–2375.

    Article  PubMed  Google Scholar 

  63. Lewis JD, Ferrara A, Peng T et al. Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916–922.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. SDI, Vector One®: Total Patient Tracker (TPT). 2010-2010. Data extracted 10.

    Google Scholar 

  65. Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of type I diabetes. Diabetes Care 1997; 20(3): 248–253.

    Article  CAS  PubMed  Google Scholar 

  66. McCulloch DK. Kurtz AB, Tattersall RB. A new approach to the treatment of nocturnal hypoglycemia using alpha-glucosidase inhibition. Diabetes Care 1983; 6(5): 483–487.

    Article  CAS  PubMed  Google Scholar 

  67. Meneilly GS, Ryan EA, Radziuk J et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000; 23(8): 1162–1167.

    Article  CAS  PubMed  Google Scholar 

  68. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. Diabetes Care 1994; 17(6): 561–566.

    Article  CAS  PubMed  Google Scholar 

  69. Holman RR. Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years. Diabetes Care 1999; 22(6): 960–964.

    Article  CAS  PubMed  Google Scholar 

  70. Chiasson JL, Josse RG, Hunt JA et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121(12): 928–935.

    Article  CAS  PubMed  Google Scholar 

  71. Demuth HU, McIntosh CH, Pederson RA. Type 2 diabetes—therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 2005; 1751(1): 33–44.

    Article  CAS  PubMed  Google Scholar 

  72. Mannucci E. Ognibene A, Cremasco F et al. Effect of metforrain on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001; 24(3): 489–494.

    Article  CAS  PubMed  Google Scholar 

  73. Raz I, Hanefeld M, Xu L et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49(11): 2564–2571.

    Article  CAS  PubMed  Google Scholar 

  74. Charbonnel B, Karasik A, Liu J et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29(12): 2638–2643.

    Article  CAS  PubMed  Google Scholar 

  75. Rosenstock J, Brazg R, Andryuk PJ et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglita/one therapy in patients with type 2 diabetes. Clin Ther 2006; 28(10): 1556–1568.

    Article  CAS  PubMed  Google Scholar 

  76. Hermansen K, Kipnes M. Luo E et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obcs Metab 2007; 9(5): 733–745.

    Article  CAS  Google Scholar 

  77. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drag-naive patients with type 2 diabetes. Diabetes Obes Metab 2008; 10(5): 376–386.

    Article  CAS  PubMed  Google Scholar 

  78. DeFronzo RA, Hissa MN, Garber AJ et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009; 32(9): 1649–1655.

    Article  CAS  Google Scholar 

  79. Chacra AR, Tan GH, Apanovitch A et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitratiou of sulphonylurea in patients with type 2 diabetes: a randomized controlled trial, Int J Clin Pract 2009; 63(9): 1395–1406.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Pratley RE, Jauffret-Kamel S, Galbreath E, et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006; 38(6): 423–428.

    Article  CAS  PubMed  Google Scholar 

  81. Pi-Sunyer FX, Schweizer A, Mills D et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76(1): 132–138.

    Article  CAS  PubMed  Google Scholar 

  82. Fonseca V, Schweizer A, Albrecht D et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50(6): l148–1155.

    Article  CAS  Google Scholar 

  83. Bosi E, Camisasca RP, Collober C et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30(4): 890–895.

    Article  CAS  PubMed  Google Scholar 

  84. Eng J, Kleinman WA. Singh L et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267(11): 7402–7405.

    CAS  PubMed  Google Scholar 

  85. Parkes DG, Pittner R, Jodka C et al. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001; 50(5): 583–589.

    Article  CAS  PubMed  Google Scholar 

  86. KoltermanOG, Buse JB, Fineman MS et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Eudocrinol Metab 2003; 88(7): 3082–3089.

    Article  CAS  Google Scholar 

  87. Xu G, Stoffers DA, Habener JF et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48(12): 2270–2276.

    Article  CAS  PubMed  Google Scholar 

  88. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28(5): 1083–1091.

    Article  CAS  PubMed  Google Scholar 

  89. Zinman B, Hoogwerf BJ, Duran GS et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146(7): 477–485.

    Article  PubMed  Google Scholar 

  90. http://www.fda.gov/CDER/Drug/InfoSheets/HCP/exenatide2008HCP.htm Accessed 2008.

  91. Stephen JM. Maxine AP. Diabetes mellitus and hypoglycemia. Current Medical Diagnosis and Treatment 2010; 1079–1121.

    Google Scholar 

  92. Linnebjerg H, Kothare PA, Skrivanek Z et al. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes. Diabet Med 2006; 23(3): 240–245.

    Article  CAS  PubMed  Google Scholar 

  93. Vilsboll T, Zdravkovic M, Le-Thi T et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608.

    Article  PubMed  CAS  Google Scholar 

  94. Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes. Diabetes Care 2009; 32(7): 1224–1230.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Bjerre Knudsen L, Madsen LW, Andersen S et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151(4): 1473–1486.

    Article  PubMed  CAS  Google Scholar 

  96. Rainer RE, Dickey R, Fineman M et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: one year, randomized controlled trial. Diabet Med 2004; 21(11): 1204–1212.

    Article  Google Scholar 

  97. Hollander PA, Levy P. Fineman MS et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003; 26(3): 784–790.

    Article  CAS  PubMed  Google Scholar 

  98. Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988; 81(2): 442–448.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Binder C. Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984; 7(2): 188–199.

    Article  PubMed  Google Scholar 

  100. Kitabchi AE, Umpierrez GE, Murphy MB et al. Management of hyperglycemic crises in patients with diabetes (Technical Review). Diabetes Care. 2001; 24: 131–153.

    Article  CAS  PubMed  Google Scholar 

  101. Greenspan FS, Gardner DG. Basic and Clinical Endocrinology. Sixth edition 2001; 661–668.

    Google Scholar 

  102. Barnett AH, Owens DR. Insulin analogues. Lancet 1997; 349: 47.

    Article  CAS  PubMed  Google Scholar 

  103. Singh SR, Ahmad F, Lal A et al. Efficacy and safety of insulin analogues for the management of diabetes mcllitus: a meta-analysis. CMAJ 2009; 180: 385.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Heinemann L. Linkeschova R, Rave K et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23(5): 644–649.

    Article  CAS  PubMed  Google Scholar 

  105. Home PD, Lagarenne P. Combined randomized controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009; 52(12): 2499–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Havelund S, Plum A, Ribel U et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004; 21: 1498.

    Article  CAS  PubMed  Google Scholar 

  107. Philis-Tsimikas A, Charpentier G, Clauson P et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006; 28(10): 1569–1581.

    Article  CAS  PubMed  Google Scholar 

  108. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26(11): 3080–3086.

    Article  CAS  PubMed  Google Scholar 

  109. Plank J, Siebenhofer A, Berghold A et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005; 165(12): 1337–1344.

    Article  CAS  PubMed  Google Scholar 

  110. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963.

    Article  PubMed  Google Scholar 

  111. Bergenstal RM, Johnson M, Powers MA et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care 2008; 31(7): 1305–1310.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Castéra V, Dutour-Meyer A, Koeppel M et al. Systemic allergy to human insulin and its rapid and long acting analogs: successful treatment by continuous subcutaneous insulin lispro infusion. Diabetes Metab 2005; 31: 391–400.

    Article  PubMed  Google Scholar 

  113. van Bon AC, Brouwer TB, von Basum G et al. Future Acceptance of an Artificial Pancreas in Adults with Type 1 Diabetes. Diabetes Technol Ther 2011; 13(7): 731–736.

    Article  PubMed  Google Scholar 

  114. Nagaya M, Katsuta H, Kaneto H et al. Adult mouse intrahepatic biliary epithelial cells induced in vitro to become insulin-producing cells. J Endocrinol 2009; 201: 37–47.

    Article  CAS  PubMed  Google Scholar 

  115. Alejandro R, Barton FB, Hering BJ et al. Update from the Collaborative Islet Transplant Registry. Transplantation 2008; 86: 1783–1788.

    Article  PubMed  Google Scholar 

  116. Ojo AO, Meier-Kriesche HU, Hanson JA et al. The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation 2001; 71: 82–90.

    Article  CAS  PubMed  Google Scholar 

  117. Larsen. Pancreas transplantation: indications and consequences. Endocr Rev 2004; 25: 919–946.

    Article  PubMed  Google Scholar 

  118. Lee HC, Kim SJ, Kim KS et al. Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue. Nature 2000; 408: 483–488.

    Article  CAS  PubMed  Google Scholar 

  119. Rahmoune H, Thompson PW, Ward JM et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin dependent diabetes. Diabetes 2005; 54: 3427–3434.

    Article  CAS  PubMed  Google Scholar 

  120. Handelsma Y, Goldberg RB, Garvey WT et al. Colesevelam hydrochloride to treat hypercholesterolemia and improve g1ycemia in prediabetes: a randomized, prospective study. Endocr Pract 2010; 16(4): 617–628. http://reference.medscape.com/medline/abstract/20634176.

    Article  Google Scholar 

  121. Bonadonna RC, Heise T, Arbet-Engel et al. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 2010; 95(11): 5028–5036. http://reference.medscape.com/medline/abstract/20739378.

    Article  CAS  PubMed  Google Scholar 

  122. http://en.wikipedia.org/wiki/Insulin_therapy#cite_note-24.

Download references

Author information

Authors and Affiliations

  1. Diabetes and Endocrinology Section, Liaquat National Hospital and Medical College, Karachi, Pakistan

    Khalid Imam

Authors
  1. Khalid Imam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Khalid Imam .

Editor information

Editors and Affiliations

  1. School of Science and Technology, Nottingham Trent University, Nottingham, UK

    Shamim I. Ahmad BSc, MSc, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Landes Bioscience and Springer Science+Business Media

About this chapter

Cite this chapter

Imam, K. (2013). Management and Treatment of Diabetes Mellitus. In: Ahmad, S.I. (eds) Diabetes. Advances in Experimental Medicine and Biology, vol 771. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5441-0_26

Download citation

Publish with us

Policies and ethics

Search

Navigation